Table 3.

Overall prostate cancer risk and the risk of advanced cancer among users of the distinct cholesterol-lowering drugs

Overall prostate cancer
Advanced prostate cancer
No. discordant pairs*OR (95% CI)No. discordant pairsOR (95% CI)
All cholesterol-lowering drugs2,369/2,2351.06 (1.00-1.13)202/2590.76 (0.64-0.91)
All statins2,253/2,0671.07 (1.00-1.16)196/2550.75 (0.62-0.91)
    Atorvastatin452/4071.10 (0.97-1.25)26/430.61 (0.37-0.98)
    Fluvastatin437/4280.99 (0.87-1.12)48/461.04 (0.71-1.54)
    Lovastatin568/5211.06 (0.94-1.18)51/820.61 (0.43-0.85)
    Pravastatin181/1601.11 (0.90-1.35)11/150.72 (0.38-1.36)
    Simvastatin1,103/1,0501.03 (0.95-1.12)94/1190.78 (0.61-1.01)
All fibrates120/1131.05 (0.86-1.27)9/120.74 (0.41-1.36)
    Bezafibrate64/571.09 (0.83-1.44)6/61.00 (0.44-2.25)
    Gemfibrozil56/521.05 (0.80-1.38)4/50.87 (0.36-2.11)
Other cholesterol-lowering drugs28/241.16 (0.80-1.68)4/31.15 (0.40-3.33)
  • NOTE: Study population of all newly diagnosed prostate cancer cases in Finland in 1995 to 2002 and their individually matched controls.

  • * As conditional logistic regression is the analysis method, the number of case-control pairs discordant to statin use is reported. Case: user-control: nonuser/Case: nonuser-control: user.

  • Adjusted for age, usage of diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, metformin, sulfonylureas, and human insulin.

  • Includes resin and acipimox user.